Ovarian cancer vaccine - Vyriad

Drug Profile

Ovarian cancer vaccine - Vyriad

Latest Information Update: 22 Jul 2016

Price : $50

At a glance

  • Originator Vyriad
  • Class Antineoplastics; Cancer vaccines; Oncolytic viruses
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Ovarian cancer

Most Recent Events

  • 19 Jul 2016 Phase-II clinical trials in Ovarian cancer in USA (Intraperitoneal) (Vyraid pipeline, July 2016) before July 2016
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top